The work, led by Won Seok Choi, Jin Yong Song, Bomi Yoon, Jae Hyang Lim and Ji-Yun Lee, was published online on 13 October 2026 as a peer-reviewed, accepted manuscript that remains subject to final editorial edits.
The team then measured airway resistance, examined lung tissue under the microscope, quantified messenger RNA expression in tissues, and analysed both serum and bronchoalveolar lavage fluid, the fluid washed from the lungs, to assess the extent of inflammation.
According to the study’s results, vinpocetine treatment reduced airway hyperresponsiveness, lessened inflammatory cell infiltration into the lungs, limited damage to bronchial and alveolar tissue, and lowered serum levels of ovalbumin-specific immunoglobulin E, the allergy-associated antibody. The drug also suppressed the expression of cytokines and chemokines, the signalling molecules that recruit and activate inflammatory cells in the airways.
To understand how vinpocetine works, the investigators turned to cell culture experiments. In A549 cells, a human alveolar epithelial cell line stimulated with human tumour necrosis factor-alpha, and in HuT78 cells, a human T cell line stimulated with anti-CD3/CD28 antibodies, they mapped the interactions between pentraxin 3 and inflammatory signalling. Their experiments revealed a mutual positive feedback loop between pentraxin 3 and tumour necrosis factor-alpha, in which each molecule promoted the production of the other.
When the researchers silenced the gene encoding pentraxin 3 in A549 cells, the cells produced less tumour necrosis factor-alpha, interleukin-8 and MCP-1, mirroring the effects of vinpocetine treatment. In HuT78 human T cells, pentraxin 3 directly increased the production of T helper 2 cytokines, the immune signals characteristic of allergic asthma, and vinpocetine reduced the expression of these cytokines.
The most decisive evidence came from genetics. The team used mice in which the gene for pentraxin 3 had been knocked out, alongside the standard mixed granulocytic asthma model. Pentraxin 3 deficiency mitigated the pathology of the disease, confirming that the protein contributes to lung inflammation in this setting. Crucially, when vinpocetine was given to the pentraxin 3-deficient mice, the drug’s pharmacological benefit disappeared, indicating that the drug’s protective effect depends on the presence of pentraxin 3 and that pentraxin 3 is the mediator of vinpocetine’s therapeutic action.
The authors conclude that pentraxin 3 plays a crucial role in the mixed granulocytic asthma model and that vinpocetine mitigates the disease by downregulating pentraxin 3 expression. They suggest that therapeutic strategies aimed at modulating pentraxin 3 may be important for treating this form of asthma, and that vinpocetine can be considered a therapeutic candidate.
Several caveats apply. The findings come from a mouse model and from human cell lines, not from patients, so the results cannot yet be extrapolated to clinical practice. The mixed granulocytic asthma model induced by ovalbumin and lipopolysaccharide captures only selected features of human severe asthma, and the study was published as an accepted manuscript that may still undergo further edits before the final version of record. Whether vinpocetine, at doses tolerable in humans, can reproduce these effects in patients remains untested.
By identifying a feedback loop between pentraxin 3 and tumour necrosis factor-alpha in epithelial cells and showing that pentraxin 3 drives T helper 2 cytokine production in T cells, the research offers a mechanistic account of how dampening this single protein can ease multiple arms of the inflammatory response.
Subject of Research: Therapeutic modulation of pentraxin 3 by vinpocetine in a murine model of allergic asthma exacerbated by lipopolysaccharide
Article Title: Modulation of pentraxin 3 by vinpocetine ameliorates lung Inflammation in murine model of allergic asthma exacerbated by lipopolysaccharide
Article References: Choi, W. S., Song, J. Y., Yoon, B., Lim, J. H., & Lee, J.-Y. (2026). Modulation of pentraxin 3 by vinpocetine ameliorates lung Inflammation in murine model of allergic asthma exacerbated by lipopolysaccharide. Biology Direct. https://doi.org/10.1186/s13062-026-01015-8
Image Credits: AI Generated
DOI: 10.1186/s13062-026-01015-8
Keywords: asthma, pentraxin 3, vinpocetine, lung inflammation, airway hyperresponsiveness, murine model, Th2 cytokines, lipopolysaccharide, ovalbumin, drug repurposing, immunology, preclinical research
News Source: Drew Townsend. (October 30, 2026). Vinpocetine Eases Lung Inflammation in Mice by Damping Pentraxin 3. Scienmag.
